RIGL250117P36000
- 0.00
- 0.000.00%
Rigel Pharmaceuticals Newsroom
Rigel Pharmaceuticals Gets FDA Orphan-Drug Designation for R289
Express News | Rigel Announces R289 Granted Orphan Drug Designation by the FDA for Mds
Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS
Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Express News | Rigel Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Rigel Pharmaceuticals, Inc. Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Dow Jumps Over 200 Points, Crude Oil Gains 1.5%
Is There An Opportunity With Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) 40% Undervaluation?
H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $57
Rigel Pharmaceuticals Reports Initial Efficacy, Safety Data From Cancer Drug Study
Rigel Pharmaceuticals Highlights Initial Data From Ongoing Phase 1b Study Evaluating R289 In LR-MDS At The 66th ASH Annual Meeting; R289 Was Generally Well Tolerated And Demonstrated Signs Of Preliminary Clinical Activity In Elderly Heavily Pretreated...
B.Riley Financial Maintains Rigel Pharmaceuticals(RIGL.US) With Hold Rating, Raises Target Price to $27
Rigel Pharmaceuticals Is Maintained at Neutral by B. Riley Securities
Rigel Pharmaceuticals Price Target Raised to $27.00/Share From $17.00 by B. Riley Securities
AppLovin, MicroStrategy, and 28 Other Stocks That Could Be Bubbles
Rigel Pharmaceuticals Says Its R289 Hematology Drug Candidate Receives Fast-Track Designation From US FDA
Express News | Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk Mds
Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS
How Much Upside Is Left in Rigel (RIGL)? Wall Street Analysts Think 28.28%
Piper Sandler Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $23